NCT05468489 2025-10-21
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Active not recruiting
Clinical Trials
19 trialsNCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
NCT06236997 2024-02-01
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05128617 2023-06-08
PROTECT-06
Institut de cancérologie Strasbourg Europe
Completed
NCT05834582 2023-04-28
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT01210768 2021-11-23
A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
TTY Biopharm
Phase 2 Unknown
NCT05124951 2021-11-18
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
Beijing Tiantan Hospital
Phase 2 Recruiting
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT04254471 2020-02-05
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Haihe Biopharma Co., Ltd.
Phase 2/3 Unknown
NCT03992911 2019-06-20
Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma
Peking University
Phase 2/3 Unknown
NCT00682981 2016-07-21
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00567554 2016-02-10
GeparQuinto
GBG Forschungs GmbH
Phase 3 Completed
NCT01204437 2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3 Completed
NCT00812266 2016-01-26
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Danish Oncological Lung Cancer Group
Phase 3 Terminated
NCT00912392 2014-09-03
Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Phase 2 Completed
NCT01917578 2013-08-06
BCSMANC
Shandong Cancer Hospital and Institute
Phase 3 Unknown
NCT00544505 2011-12-13
Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)
King Faisal Specialist Hospital & Research Center
Phase NA Unknown